Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Committee Review Expected Prior To Tysabri Market Re-Entry

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec and Elan expect Tysabri will be subject to an FDA advisory committee review before the multiple sclerosis therapy is allowed back on the market

You may also be interested in...



Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program

The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.

Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program

The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel